NIH funding opportunity – Indo-U.S. Vaccine Action Program (VAP) Small Research Grant Program (R03)

April 11, 2016 by School of Medicine Webmaster

This initiative offers to support VAP research activities and encourages research leading to the development of new and improved vaccines and related products, and technologies to combat infectious diseases of importance in India, the U.S., the South Asian region and globally.  While applicants must provide evidence of ongoing or proposed scientific collaborations specific to the research proposed in the grant application, this initiative will not require joint application, review and funding of applications by the U.S. and India as was required in previous VAP-supported research projects. Standard NIH application and review procedures will be followed. NIAID will fund the grants supported by this FOA.

Any area of basic, translational, clinical, or epidemiological vaccine research may be proposed under this program.  Examples of possible research topics include, but are not limited to:

  • Discovery, demonstration of the proof of principle, development of novel manufacturing processes, evaluation of the safety and efficacy and demonstration of the effectiveness of the use of new and improved vaccines to prevent:
  • Tuberculosis
  • Pandemic and interpandemic influenza
  • Dengue and Dengue Hemorrhagic Fever (DHF)
  • Malaria
  • Enteric diseases
  • Discovery and/or development of vaccine adjuvants promoting mucosal or systemic responses; analysis of their mechanism of action; optimization of vaccine adjuvants to increase efficacy while reducing reactogenicity; development of in vitro assays for evaluating adjuvanticity and/or reactogenicity; identification of correlates of adjuvanticity;
  • Characterization of local and/or systemic immune responses and regulatory mechanisms in infants, compared to older children or adults, to vaccines or natural exposure/illness due to infectious diseases;
  • Mechanisms of systemic or mucosal immune response across the lifespan to infection or vaccination, including characterization of mucosal vaccine immune responses, and correlates/surrogates of mucosal immune responses;
  • New manufacturing and vaccine delivery technology;
  • Effectiveness of the introduction of new and improved vaccines into public health immunization programs;
  • Epidemiology of infectious disease in the human population.

Deadline:  standard dates apply


Filed Under: Funding Opportunities